Boston Scientific Corporation (NYSE: BSX) Fourth quarter financial results:
On Friday, Boston Scientific Corporation (NYSE: BSX) stock changed 0.28% to recent value of $42.62. There are 1393.1M shares outstanding and 1390.6M shares are floated in market. BSX over recent time; they noted that 7278441 shares changed at hands contradiction to its average trading volume of 7030.03K.
Boston Scientific Corporation (BSX) generated sales of $2.905B during the fourth quarter of 2019. This represents growth of 13.4 percent on a stated basis, 14.1 percent on an operational 1 basis and 7.3 percent on an organic 2 basis, all contrast to the previous year period. The company stated GAAP earnings of $3.996B or $2.83 per share (EPS), contrast to GAAP earnings of $386M or $0.27 per share a year ago and achieved adjusted earnings per share of $0.46 for the period, contrast to $0.39 a year ago. Stated GAAP earnings include a important net income tax benefit explained in the Use of Non-GAAP Financial Measures section below.
For the full year 2019, the company generated sales of $10.735B. This represents growth of 9.3 percent on a stated basis, 11.1 percent on an operational 1 basis and 7.3 percent on an organic 2 basis, all contrast to the previous year period. The company stated GAAP earnings of $3.33 per share, inclusive of the net income tax benefit mentioned above, contrast to $1.19 in 2018 and delivered full year adjusted earnings per share of $1.58, contrast to $1.47 in 2018. Full year 2018 GAAP and adjusted earnings per share included a $0.07 net tax benefit. 3
Fourth quarter financial results and recent developments:
Stated fourth quarter sales of $2.905B , representing a raise of 13.4 percent on a stated basis, contrast to the company’s guidance range of 13 to 15 percent; 14.1 percent on an operational basis; and 7.3 percent on an organic basis, contrast to the company’s guidance range of 8 to 9 percent, all contrast to the previous year period.
Stated fourth quarter GAAP earnings of $2.83 per share, contrast to the company’s guidance range of $0.22 to $0.25 per share. Stated GAAP earnings include net litigation charges of $169M, or $0.12 per share, primarily related to the before revealed Channel Medsystems, Inc. matter, and a net income tax benefit of $4.102B , or $2.90 per share, explained in the Use of Non-GAAP Financial Measures section below. Achieved adjusted earnings per share of $0.46 per share, contrast to the guidance range of $0.42 to $0.45 per share.
Achieved fourth quarter revenue growth in all sections 5, contrast to the previous year period:
Delivered fourth quarter Medical Device 5 revenue growth in all regions, contrast to the previous year period:
Received U.S. Food and Drug Administration (FDA) 510(k) clearance and Breakthrough Device Designation, and CE Mark for the EXALT” Model D Duodenoscope , the first and only single-use duodenoscope. Initiated limited market release, including a successful first case in patient undergoing endoscopic retrograde cholangiopancreatography (ERCP), a procedure performed over 1.5M times worldwide each year to diagnose and treat pancreatic and biliary conditions.
Positive 12-month data from the investigator-sponsored COMPARE trial, demonstrating non-inferiority of the low-dose paclitaxel-coated Ranger” Drug-Coated Balloon (DCB) (2.0 µg/mm2) contrast to the higher dose IN.PACT” DCB (Medtronic) balloon (3.5 µg/mm2), was presented at the Leipzig Interventional Course (LINC) Congress. COMPARE is the first randomized controlled head-to-head trial comparing two drug-coated balloon technologies.
Presented at the 2020 Gastrointestinal Cancers Symposium positive data on the impact of personalized radiation dosing using TheraSphere” Yttrium-90 Glass Microspheres from the investigator-sponsored DOSISPHERE-01 trial. Data demonstrated personalized dosing of radiation increased overall survival of patients with the most ordinary type of liver cancer, when contrast to patients who received a standardized dose.
Reported plans to initiate CHAMPION-AF–a randomized head-to-head trial of the WATCHMAN FLX” Left Atrial Appendage Closure Device vs. direct oral anticoagulants–in the second half of 2020. The global trial is designed to study stroke risk reduction efficacy and bleeding endpoints in lower-risk patients with non-valvular atrial fibrillation.
Received Japanese Pharmaceuticals and Medical Devices Agency (PMDA) authorization and positive reimbursement in Japan for the LOTUS Edge ” Aortic Valve System , a minimally invasive transcatheter aortic valve replacement (TAVR) technology for patients with severe aortic stenosis.
Received FDA authorization for the INGEVITY”+ active fixation pacing lead for use with pacemakers and defibrillators. Built on the INGEVITY” platform with proven longevity, the new lead is designed to offer a more predictable implant experience for physicians.
Received CE Mark for the POLARx” Cryoablation System , which is indicated for the treatment of patients with paroxysmal atrial fibrillation (AF), an intermittent form of AF which causes an irregular and often abnormally fast heart rate.
Reported at the North American Neuromodulation Society (NANS) YearlyMeeting results of the COMBO randomized clinical trial showing that Combination Therapy delivered by the Spectra WaveWriter” Spinal Cord Stimulator (SCS) System achieved an 88% responder rate in treating chronic pain–much higher than monotherapy alone. Also at NANS, reported an exclusive joint venture with IBM Research to develop AI-generated predictive algorithms for highly personalized chronic pain therapy.
Completed a public offering of ¬900M aggregate principal amount of 0.625% Senior Notes due 2027, and completed cash tender offer for about $1.0B aggregate principal amount of certain outstanding senior notes.
Completed the sale of BTG’s royalty revenue stream associated with Zytiga® for $256M in cash, the proceeds from which were used to repay portions of outstanding debt.
Is BSX Stock Risky?
Currently BSX has beta value of 0.79. A beta of 1.0 tells you that a stock has been going up and down with the overall stock market. A stock with a beta between 0.0 and 1.0 has smaller ups and downs. A beta greater than 1.0 has wider price swings. You invest to earn a return on your money, but returns are not the only consideration. Risk and return are connected. Generally, the higher the risk of an investment, the higher the potential return. Here beta – measures how the stock is doing compared to a given benchmark, such as the S&P TSX Composite Index. Stocks with a negative beta are moving opposite to the index. When you invest in a stock, you could lose all of your money – in some cases, more than you invested. Before you buy a stock, understand the risks and decide if they are risks you are comfortable taking.
Analyst recommendations as reported on FINVIZ are rated on a 1 to 5 scale. 1 is equivalent to a Strong Buy rating, 3 a hold rating, and 5 a Strong Sell rating. The consensus recommendation is the average rating on a stock by the analyst community. Analyst mean recommendation for this stock stands at 1.6. A stock rating will usually tell the investor how well a stock’s market value relates to what analysts believe is a fair value for the stock, based on an objective evaluation of the company.
Simple Moving Average:
The stock disclosed a move of -2.96% away from 50 day moving average and 1.93% away from 200 day moving average. Moving closer, we can see that shares have been trading -0.21% away off 20-day moving average. Traders and technical analysts have the ability to use volume to help measure the strength of a particular move. Investors may also view volume levels when the stock price is nearing significant support or resistance levels, in order to confirm a breakout in either direction.
BSX ’s shares are at -0.02% for the quarter and driving a 6.23% return over the course of the past year and is now at -5.75% since this point in 2019. The average volatility for the week and month was at 1.04% and -3.25% respectively.